Intech Biopharm Ltd Cash Flow-to-Debt Ratio
Intech Biopharm Ltd cash flow-to-debt ratio. Intech Biopharm Ltd (6461) has a Cash Flow-to-Debt Ratio of -0.06x as of March 2026, meaning its operating cash flow of NT$-84.50 Million could theoretically repay 0% of its total liabilities (NT$1.34 Billion) in one year. See 6461 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Intech Biopharm Ltd (2017–2025)
Cash flow-to-debt ratio of Intech Biopharm Ltd from 2017 to 2025. Historical debt coverage capacity for Intech Biopharm Ltd across 9 annual periods. Also explore net asset momentum of Intech Biopharm Ltd to track the company's year-over-year net asset growth rate.
Intech Biopharm Ltd Cash Flow-to-Debt Ratio by Year (2017–2025)
Intech Biopharm Ltd cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for Intech Biopharm Ltd. For the full cash flow conversion analysis, see Intech Biopharm Ltd cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.29x | NT$-361.13 Million | NT$1.25 Billion | ▼ -69.7% |
| 2024 | -0.17x | NT$-269.22 Million | NT$1.58 Billion | ▼ -28.7% |
| 2023 | -0.13x | NT$-204.13 Million | NT$1.54 Billion | ▼ -5.5% |
| 2022 | -0.13x | NT$-190.39 Million | NT$1.52 Billion | ▲ +21.0% |
| 2021 | -0.16x | NT$-200.61 Million | NT$1.26 Billion | ▼ -22.6% |
| 2020 | -0.13x | NT$-167.38 Million | NT$1.29 Billion | ▲ +29.0% |
| 2019 | -0.18x | NT$-189.09 Million | NT$1.04 Billion | ▲ +19.6% |
| 2018 | -0.23x | NT$-232.43 Million | NT$1.02 Billion | ▼ -38.6% |
| 2017 | -0.16x | NT$-145.29 Million | NT$887.48 Million | — |